Sat.Oct 28, 2023

article thumbnail

Nirsevimab Demonstrates Lasting Efficacy in Infants Through First RSV Season

Drug Topics

The drug, marketed as Beyfortus, was approved by the FDA in July for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

FDA 247
article thumbnail

An Ask Me Anything with STAT’s Nicholas St. Fleur

STAT

Recently, STAT launched a brand-new home for our subscribers to connect with each other and with their favorite STAT journalists. It’s called, appropriately, STAT+ Connect. There, you can find job postings; comment on STAT articles (since we have closed comments on article pages); discuss news events with other people who work in biotech, pharma, public health advocacy, PR, and more; read insights and extra material posted by STAT reporters and editors; and watch events, including live in

106
106
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Patient-Centricity: Evolving Digital Communication in Pharma

Pharma Marketing Network

Patient-centricity is a concept that is gaining traction in the pharmaceutical industry. It is a shift from a traditional focus on drug development and marketing to a focus on the patient’s needs. This shift is being driven by advances in digital communication, which are allowing companies to better understand and meet the needs of their patients. In this article, we will explore the concept of patient-centricity, its impact on digital communication in pharma, the benefits it brings, and the cha

article thumbnail

Injected Version of Eisai/Biogen Alzheimer’s Drug Works as Well as IV Leqembi

Roots Analysis

On 26 October 2023, Eisai and Biogen’s Alzheimer’s drug, Leqembi, was found to be as effective as the current intravenous administration in removing toxic brain plaques. However, the review conducted by the drugmakers revealed that the rates of serious side effects were higher when using the drug in its subcutaneous injection form. The company’s analysis compared data from 72 early Alzheimer’s patients who received Leqembi through subcutaneous injection to prior pivotal t

40
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven